Testing a diabetes-style shot to boost brain immunity in early Alzheimer’s
Part of Brain & nervous system, Mental health clinical trials.
This Phase 1 study tests whether stimulating the immune system (through a receptor called TLR9) is safe and may affect brain changes in people with early Alzheimer’s. It mainly enrolls older adults with memory impairment confirmed by specific amyloid imaging.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Ages 65 to 85
- Have early Alzheimer’s—either MCI due to Alzheimer’s or mild Alzheimer’s dementia—based on set diagnostic standards
- Memory testing: MoCA score 17 or higher
- Your brain amyloid test (Florbetaben PET or another PET amyloid scan) must be positive and done within 1 year
- Have a study partner who knows you well, can share updates about memory and daily function, and can join clinic visits or be reachable by phone
- Be able to do study procedures, including MRI scans (not be unable to have MRI) and be willing/able to give consent (or assent if needed)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests whether an existing type of anti-viral medicine (nucleoside reverse transcriptase inhibitors) can help people with early Alzheimer’s disease. It also focuses on safety and proper dosing while measuring brain-related changes and memory-related symptoms.
This study tests a new medication, CORT108297, that may help protect the brain from the harmful effects of stress in people at risk for Alzheimer's disease. It is looking for adults age 55 and older who either have mild memory problems or are healthy but have a family history, APOE4 gene, or memory concerns.
This trial looks for signs of Alzheimer’s disease in the brain by using memory and thinking tests, and related study procedures. It may help researchers find better ways to identify Alzheimer’s-related changes earlier.
This Phase 2 study uses repeated brain MRI scans to track “microglial activation,” which is a marker of brain immune/inflammation activity, in different Alzheimer’s-related conditions. It may help researchers understand how brain inflammation changes over time and differs between people with these clinical variants.
This trial tests a new investigational drug, BMS-986446, given as a single dose to healthy volunteers and multiple doses to people with early Alzheimer's disease. It aims to understand how the drug moves in the body, its safety, and whether it triggers an immune response, which could help guide future treatment for Alzheimer's.
This trial tests an investigational injection for people in the early stages of Alzheimer's. It aims to see if the drug can safely slow down memory loss and brain changes.
Hear when a new Mild Cognitive Impairment trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.